Products
Lomvastomig Biosimilar Bispecific Antibody (PD-1 × TIM-3) for Research
Cat No.: GMP-Bios-INN-1265
Anti-PDCD1/CD279/PD1 therapeutic antibody (Pre-made Lomvastomig biosimilar,Bispecific mAb with Domain Crossover) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Lomvastomig (development code RG7769) is a bispecific antibody targeting PD-1 (PDCD1) and TIM-3 (HAVCR2). It is developed by Roche for non-small cell lung cancer and small cell lung cancer. It is in Phase II clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1265-1mg | 1mg | |
| GMP-Bios-INN-1265-10mg | 10mg | |
| GMP-Bios-INN-1265-100mg | 100mg | |
| GMP-Bios-INN-1265-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Lomvastomig biosimilar, Bispecific mAb with Domain Crossover, Anti-PDCD1/CD279/PD1;HAVCR2/TIM3 Antibody: Anti-PD-1/CD279/PDCD1/Programmed cell death protein 1 therapeutic antibody |
| INN Name | Lomvastomig |
| Target | PDCD1/CD279/PD1;HAVCR2/TIM3 |
| Format | Bispecific mAb with Domain Crossover |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1;G1 |
| VD LC | Kappa;Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2022 |
| Year Recommended | 2023 |
| Companies | Roche |
| Conditions Approved | na |
| Conditions Active | Non-small cell lung cancers;Small cell lung cancers;Squamous cell carcinoma |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
